Blis applies for ear bacterium patent

By NZPA

Monday 24th February 2003

Just a week after launching its second product, biotech Blis Technologies today lodged a patent for a bacterium to combat ear infections.

The bacterium, which appears naturally in the nasal passages of healthy children, has shown promise in preventing ear infections and sinusitis -- opening up a potential gold mine for the company.

"Ear infections account for up to 30 percent of children's visits to the doctor in America, second only to the common cold and there's no reason to believe they are any less prevalent in New Zealand," Blis chief executive Kelvin Moffatt said.

Early lab trials show the bacterium inhibits a variety of bugs that lead to ear infections. Used after a course of antibiotics, it could help replenish the body's natural defences, Mr Moffatt said.

Pilot trials of people suffering chronic ear infections will begin soon.

Blis Technologies was formed in June 2000 to pursue the commercialisation of Blis (bacteriocin-like inhibitory substances).

It listed in 2001 and key shareholders include Otago University, with 20 percent; Southern Capital Ltd on 15.7 percent; and Dunedin entrepreneur Howard Paterson, who owns 11 percent.

Last week it unveiled its second product, Blis Bio Restore, which restores naturally occurring intestinal and oral bacteria following antibiotic use. It goes on sale next month, alongside the firm's Blis K12 Throat Guard.

Blis said today it has also lodged a patent for a product containing a bacterium that assists in preventing tooth decay. This product is about to undergo clinical trials in association with the University of Otago Dental School.

Comments from our readers

No comments yet